دورية أكاديمية
Heterogeneity in Radiotherapeutic Parameter Assumptions in Cost-Effectiveness Analyses in Prostate Cancer: A Call for Uniformity.
| العنوان: | Heterogeneity in Radiotherapeutic Parameter Assumptions in Cost-Effectiveness Analyses in Prostate Cancer: A Call for Uniformity. |
|---|---|
| المؤلفون: | Butala AA; Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA., Huang CC; Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN, USA., Bryant CM; Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL, USA., Henderson RH; Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL, USA., Hoppe BS; Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL, USA., Mendenhall NP; Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL, USA., Vapiwala N; Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA., Mailhot Vega RB; Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL, USA. Electronic address: rbmailhot@floridaproton.org. |
| المصدر: | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2022 Feb; Vol. 25 (2), pp. 171-177. Date of Electronic Publication: 2021 Oct 22. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Systematic Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 100883818 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1524-4733 (Electronic) Linking ISSN: 10983015 NLM ISO Abbreviation: Value Health Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Jan./Feb. 2011- : New York : Elsevier Original Publication: Malden, MA : Blackwell Science, c1998- |
| مواضيع طبية MeSH: | Prostatic Neoplasms/*economics , Prostatic Neoplasms/*radiotherapy, Adenocarcinoma/economics ; Adenocarcinoma/radiotherapy ; Aged ; Cost-Benefit Analysis ; Humans ; Male ; Models, Theoretical ; Neoplasm Staging ; Quality-Adjusted Life Years |
| مستخلص: | Objectives: Cost-effectiveness analyses (CEAs) may provide useful data to inform management decisions depending on the robustness of a model's input parameters. We sought to determine the level of heterogeneity in health state utility values, transition probabilities, and cost estimates across published CEAs assessing primarily radiotherapeutic management strategies in prostate cancer. Methods: We conducted a systematic review of prostate cancer CEAs indexed in MEDLINE between 2000 and 2018 comparing accepted treatment modalities across all cancer stages. Search terms included "cost effectiveness prostate," "prostate cancer cost model," "cost utility prostate," and "Markov AND prostate AND (cancer OR adenocarcinoma)." Included studies were agreed upon. A Markov model was designed using the parameter estimates from the systematic review to evaluate the effect of estimate heterogeneity on strategy cost acceptability. Results: Of 199 abstracts identified, 47 publications were reviewed and 37 were included; 508 model estimates were compared. Estimates varied widely across variables, including gastrointestinal toxicity risk (0%-49.5%), utility of metastatic disease (0.25-0.855), intensity-modulated radiotherapy cost ($21 193-$61 996), and recurrence after external-beam radiotherapy (1.5%-59%). Multiple studies assumed that different radiotherapy modalities delivering the same dose yielded varying cancer control rates. When using base estimates for similar parameters from included studies, the designed model resulted in 3 separate acceptability determinations. Conclusions: Significant heterogeneity exists across parameter estimates used to perform CEAs evaluating treatment for prostate cancer. Heterogeneity across model inputs yields variable conclusions with respect to the favorability and cost-effectiveness of treatment options. Decision makers are cautioned to review estimates in CEAs to ensure they are up to date and relevant to setting and population. (Copyright © 2021 ISPOR–The International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc. All rights reserved.) |
| معلومات مُعتمدة: | UL1 TR002529 United States TR NCATS NIH HHS |
| فهرسة مساهمة: | Keywords: cost-effectiveness analysis; prostate cancer; radiation therapy |
| تواريخ الأحداث: | Date Created: 20220131 Date Completed: 20220218 Latest Revision: 20220218 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1016/j.jval.2021.08.010 |
| PMID: | 35094789 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1524-4733 |
|---|---|
| DOI: | 10.1016/j.jval.2021.08.010 |